Global Rapid-dissolving Tablets Market Research Report 2022

Rapid-dissolving Tablets is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.
Due to the COVID-19 pandemic, the global Rapid-dissolving Tablets market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Rapid-dissolving Tablets market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Rapid-dissolving Tablets landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Anti-Psychotics Drug accounting for % of the Rapid-dissolving Tablets global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While CNS Diseases segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Rapid-dissolving Tablets include Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company and AstraZeneca, etc. In terms of revenue, the global 3 largest players have a % market share of Rapid-dissolving Tablets in 2021.
This report focuses on Rapid-dissolving Tablets volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Rapid-dissolving Tablets market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Rapid-dissolving Tablets Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
Segment by Application
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Teva
Merck
Mylan
Pfizer
Johnson and Johnson
GSK
Otsuka
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Conquer

Frequently Asked Questions